Corrigendum to "A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)": [ESMO Open. Volume 10, Issue 9, (September 2025) 105571]
关于“结直肠癌患者体内剂量递增的双周三氟尿苷/替吡嘧啶联合贝伐珠单抗 II 期研究（E-BiTS 研究）”的更正：[ESMO Open. 第 10 卷，第 9 期，（2025 年 9 月）105571]
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105912
Wakabayashi, M; Taniguchi, H; Makiyama, A; Sunakawa, Y; Takeda, H; Arimizu, K; Okumura, Y; Inagaki, C; Mitani, S; Kudo, T; Yuki, S; Akazawa, N; Kudo, C; Mori, K; Matsuda, T; Muro, K
